You are leaving the Blue Earth Therapeutics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Therapeutics. The site you are linking to is not controlled or endorsed by Blue Earth Therapeutics and Blue Earth Therapeutics is not responsible for the content provided on that site.

ACCEPT
CANCEL

Designed to make your life much easier.

This page is intended for Healthcare Professionals only. Are you a Healthcare Professional?

Yes No

More bang for your becquerel:
Improving the therapeutic index with novel radiopharmaceuticals

Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of 177Lu-rhPSMA-10.1 in comparison with 177Lu-PSMA-I&T

2022 SNMMI Meeting

Enhanced therapeutic response to 177Lu-rhPSMA-10.1 in pre-clinical models of prostate cancer

2023 SNMMI Meeting

Preclinical evaluation of 225Ac-rhPSMA-10.1, a novel radiohybrid PSMA compound for targeted alpha therapy of prostate cancer

2023 EANM Meeting

PP-UK-0671 / November 2023
BET Logo White-1

QUICK LINKS

PRIVACY STATEMENT
COOKIE POLICY
INTELLECTUAL PROPERTY
BRACCO CODE OF ETHICS

CONTACT US

BLUE EARTH THERAPEUTICS LTD.
MAGDALEN CENTRE
ROBERT ROBINSON AVENUE
THE OXFORD SCIENCE PARK, OXFORD
OX4 4GA, UK


TEL: 01865 634500
EMAIL: CONTACT@BLUEEARTHTX.COM

© Blue Earth Therapeutics 2024. All Rights Reserved. Developed by RevM